NCCN Adds MammaPrint Gene Expression Assay to Breast Cancer Guidelines
OncLive,
The National Comprehensive Cancer Network (NCCN) breast cancer guidelines issued February 7, 2003, added the MammaPrint…
The National Comprehensive Cancer Network (NCCN) breast cancer guidelines issued February 7, 2003, added the MammaPrint…
The phase 3 MINDACT trial (NCT00433589) demonstrated that patients with early-stage breast cancer who have ultralow risk…
A 70-gene signature indicated women with early-stage breast cancer who have ultralow risk disease and would demonstrate an…
At a median follow-up of 8.7 years, the 8-year distant metastasis-free interval (DMFI) rate in patients with ultralow-risk…